Form 4: Compass Therapeutics Director Richard S. Lindahl Acquires 40,000 Stock Options

Director Richard S. Lindahl of Compass Therapeutics, Inc. acquired 40,000 stock options on February 11, 2025, according to a Form 4 filing.

Summary

• Richard S. Lindahl, a director of Compass Therapeutics, Inc., acquired 40,000 stock options on February 11, 2025.
• The options have an exercise price of $3.65.
• The options vest over 48 months, starting March 11, 2025.
• The options expire on February 11, 2035.
• Following the transaction, Lindahl directly owns 40,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions. It indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like Compass Therapeutics.
• The vesting schedule of 48 months is also typical in the industry, aligning executive incentives with long-term company performance.
• Comparing the size of the grant to similar companies would require further analysis of Compass Therapeutics' compensation policies and peer group data.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
• The transaction itself has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates